Industry Research Reports

Home > Reports > Pharma & Healthcare > Adenovirus Vector Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Adenovirus Vector Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-14

Pages: 94 Pages

Report ld: 2632111

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Adenovirus vector vaccine refers to the adenovirus as the carrier, the protective antigen gene is recombinant into the adenovirus genome, using the recombinant adenovirus can express the protective antigen gene made of vaccine.The characteristics of adenovirus vector vaccine showed that the adenovirus vector carrying various antigens can stimulate the body to produce strong humoral immunity or cellular immunity.In addition, since adenovirus vector can infect the respiratory tract and intestinal cells, it can facilitate immunity through the mucosa and induce the body to produce mucosal and systemic immune responses.

The global market for Adenovirus Vector Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Adenovirus Vector Vaccine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Adenovirus Vector Vaccine by region & country, by Type, and by Application.

The Adenovirus Vector Vaccine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adenovirus Vector Vaccine.

Market Segmentation

Report Metric
Details
Report Title
Adenovirus Vector Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Adenovirus Vector Vaccine Companies Covered
Johnson & Johnson, CanSino Biologics, Greffex, BravoBio, Altimmune
Global Adenovirus Vector Vaccine Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Adenovirus Vector Vaccine Market, Segment by Type
Being Developed

Preclinical

Clinical I

Clinical II
Global Adenovirus Vector Vaccine Market, Segment by Application
Pharmaceutical And Biotechnology Companies

Hospital

Academic And Research Organizations

Other
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Adenovirus Vector Vaccine manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Adenovirus Vector Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Adenovirus Vector Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Adenovirus Vector Vaccine Product Introduction
    1.2 Global Adenovirus Vector Vaccine Market Size Forecast
    1.3 Adenovirus Vector Vaccine Market Trends & Drivers
        1.3.1 Adenovirus Vector Vaccine Industry Trends
        1.3.2 Adenovirus Vector Vaccine Market Drivers & Opportunity
        1.3.3 Adenovirus Vector Vaccine Market Challenges
        1.3.4 Adenovirus Vector Vaccine Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Adenovirus Vector Vaccine Players Revenue Ranking (2023)
    2.2 Global Adenovirus Vector Vaccine Revenue by Company (2019-2024)
    2.3 Key Companies Adenovirus Vector Vaccine Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Adenovirus Vector Vaccine Product Offered
    2.5 Key Companies Time to Begin Mass Production of Adenovirus Vector Vaccine
    2.6 Adenovirus Vector Vaccine Market Competitive Analysis
        2.6.1 Adenovirus Vector Vaccine Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Adenovirus Vector Vaccine Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adenovirus Vector Vaccine as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Being Developed
        3.1.2 Preclinical
        3.1.3 Clinical I
        3.1.4 Clinical II
    3.2 Global Adenovirus Vector Vaccine Sales Value by Type
        3.2.1 Global Adenovirus Vector Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Adenovirus Vector Vaccine Sales Value, by Type (2019-2030)
        3.2.3 Global Adenovirus Vector Vaccine Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Pharmaceutical And Biotechnology Companies
        4.1.2 Hospital
        4.1.3 Academic And Research Organizations
        4.1.4 Other
    4.2 Global Adenovirus Vector Vaccine Sales Value by Application
        4.2.1 Global Adenovirus Vector Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Adenovirus Vector Vaccine Sales Value, by Application (2019-2030)
        4.2.3 Global Adenovirus Vector Vaccine Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Adenovirus Vector Vaccine Sales Value by Region
        5.1.1 Global Adenovirus Vector Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Adenovirus Vector Vaccine Sales Value by Region (2019-2024)
        5.1.3 Global Adenovirus Vector Vaccine Sales Value by Region (2025-2030)
        5.1.4 Global Adenovirus Vector Vaccine Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Adenovirus Vector Vaccine Sales Value, 2019-2030
        5.2.2 North America Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Adenovirus Vector Vaccine Sales Value, 2019-2030
        5.3.2 Europe Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Adenovirus Vector Vaccine Sales Value, 2019-2030
        5.4.2 Asia Pacific Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Adenovirus Vector Vaccine Sales Value, 2019-2030
        5.5.2 South America Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Adenovirus Vector Vaccine Sales Value, 2019-2030
        5.6.2 Middle East & Africa Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Adenovirus Vector Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Adenovirus Vector Vaccine Sales Value
    6.3 United States
        6.3.1 United States Adenovirus Vector Vaccine Sales Value, 2019-2030
        6.3.2 United States Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Adenovirus Vector Vaccine Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Adenovirus Vector Vaccine Sales Value, 2019-2030
        6.4.2 Europe Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Adenovirus Vector Vaccine Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Adenovirus Vector Vaccine Sales Value, 2019-2030
        6.5.2 China Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Adenovirus Vector Vaccine Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Adenovirus Vector Vaccine Sales Value, 2019-2030
        6.6.2 Japan Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Adenovirus Vector Vaccine Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Adenovirus Vector Vaccine Sales Value, 2019-2030
        6.7.2 South Korea Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Adenovirus Vector Vaccine Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Adenovirus Vector Vaccine Sales Value, 2019-2030
        6.8.2 Southeast Asia Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Adenovirus Vector Vaccine Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Adenovirus Vector Vaccine Sales Value, 2019-2030
        6.9.2 India Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Adenovirus Vector Vaccine Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Johnson & Johnson
        7.1.1 Johnson & Johnson Profile
        7.1.2 Johnson & Johnson Main Business
        7.1.3 Johnson & Johnson Adenovirus Vector Vaccine Products, Services and Solutions
        7.1.4 Johnson & Johnson Adenovirus Vector Vaccine Revenue (US$ Million) & (2019-2024)
        7.1.5 Johnson & Johnson Recent Developments
    7.2 CanSino Biologics
        7.2.1 CanSino Biologics Profile
        7.2.2 CanSino Biologics Main Business
        7.2.3 CanSino Biologics Adenovirus Vector Vaccine Products, Services and Solutions
        7.2.4 CanSino Biologics Adenovirus Vector Vaccine Revenue (US$ Million) & (2019-2024)
        7.2.5 CanSino Biologics Recent Developments
    7.3 Greffex
        7.3.1 Greffex Profile
        7.3.2 Greffex Main Business
        7.3.3 Greffex Adenovirus Vector Vaccine Products, Services and Solutions
        7.3.4 Greffex Adenovirus Vector Vaccine Revenue (US$ Million) & (2019-2024)
        7.3.5 BravoBio Recent Developments
    7.4 BravoBio
        7.4.1 BravoBio Profile
        7.4.2 BravoBio Main Business
        7.4.3 BravoBio Adenovirus Vector Vaccine Products, Services and Solutions
        7.4.4 BravoBio Adenovirus Vector Vaccine Revenue (US$ Million) & (2019-2024)
        7.4.5 BravoBio Recent Developments
    7.5 Altimmune
        7.5.1 Altimmune Profile
        7.5.2 Altimmune Main Business
        7.5.3 Altimmune Adenovirus Vector Vaccine Products, Services and Solutions
        7.5.4 Altimmune Adenovirus Vector Vaccine Revenue (US$ Million) & (2019-2024)
        7.5.5 Altimmune Recent Developments

 8 Industry Chain Analysis
    8.1 Adenovirus Vector Vaccine Industrial Chain
    8.2 Adenovirus Vector Vaccine Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Adenovirus Vector Vaccine Sales Model
        8.5.2 Sales Channel
        8.5.3 Adenovirus Vector Vaccine Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Adenovirus Vector Vaccine Market Trends
    Table 2. Adenovirus Vector Vaccine Market Drivers & Opportunity
    Table 3. Adenovirus Vector Vaccine Market Challenges
    Table 4. Adenovirus Vector Vaccine Market Restraints
    Table 5. Global Adenovirus Vector Vaccine Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Adenovirus Vector Vaccine Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Adenovirus Vector Vaccine Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Adenovirus Vector Vaccine Product Type
    Table 9. Key Companies Time to Begin Mass Production of Adenovirus Vector Vaccine
    Table 10. Global Adenovirus Vector Vaccine Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adenovirus Vector Vaccine as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Adenovirus Vector Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Adenovirus Vector Vaccine Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Adenovirus Vector Vaccine Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Adenovirus Vector Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Adenovirus Vector Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Adenovirus Vector Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Adenovirus Vector Vaccine Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Adenovirus Vector Vaccine Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Adenovirus Vector Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Adenovirus Vector Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Adenovirus Vector Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Adenovirus Vector Vaccine Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Adenovirus Vector Vaccine Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Adenovirus Vector Vaccine Sales Value by Region (2019-2024) & (%)
    Table 27. Global Adenovirus Vector Vaccine Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Adenovirus Vector Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Adenovirus Vector Vaccine Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Adenovirus Vector Vaccine Sales Value, (2025-2030) & (US$ Million)
    Table 31. Johnson & Johnson Basic Information List
    Table 32. Johnson & Johnson Description and Business Overview
    Table 33. Johnson & Johnson Adenovirus Vector Vaccine Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Adenovirus Vector Vaccine Business of Johnson & Johnson (2019-2024)
    Table 35. Johnson & Johnson Recent Developments
    Table 36. CanSino Biologics Basic Information List
    Table 37. CanSino Biologics Description and Business Overview
    Table 38. CanSino Biologics Adenovirus Vector Vaccine Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Adenovirus Vector Vaccine Business of CanSino Biologics (2019-2024)
    Table 40. CanSino Biologics Recent Developments
    Table 41. Greffex Basic Information List
    Table 42. Greffex Description and Business Overview
    Table 43. Greffex Adenovirus Vector Vaccine Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Adenovirus Vector Vaccine Business of Greffex (2019-2024)
    Table 45. Greffex Recent Developments
    Table 46. BravoBio Basic Information List
    Table 47. BravoBio Description and Business Overview
    Table 48. BravoBio Adenovirus Vector Vaccine Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Adenovirus Vector Vaccine Business of BravoBio (2019-2024)
    Table 50. BravoBio Recent Developments
    Table 51. Altimmune Basic Information List
    Table 52. Altimmune Description and Business Overview
    Table 53. Altimmune Adenovirus Vector Vaccine Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Adenovirus Vector Vaccine Business of Altimmune (2019-2024)
    Table 55. Altimmune Recent Developments
    Table 56. Key Raw Materials Lists
    Table 57. Raw Materials Key Suppliers Lists
    Table 58. Adenovirus Vector Vaccine Downstream Customers
    Table 59. Adenovirus Vector Vaccine Distributors List
    Table 60. Research Programs/Design for This Report
    Table 61. Key Data Information from Secondary Sources
    Table 62. Key Data Information from Primary Sources
    Table 63. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Adenovirus Vector Vaccine Product Picture
    Figure 2. Global Adenovirus Vector Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Adenovirus Vector Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 4. Adenovirus Vector Vaccine Report Years Considered
    Figure 5. Global Adenovirus Vector Vaccine Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Adenovirus Vector Vaccine Revenue in 2023
    Figure 7. Adenovirus Vector Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Being Developed Picture
    Figure 9. Preclinical Picture
    Figure 10. Clinical I Picture
    Figure 11. Clinical II Picture
    Figure 12. Global Adenovirus Vector Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 13. Global Adenovirus Vector Vaccine Sales Value Market Share by Type, 2023 & 2030
    Figure 14. Product Picture of Pharmaceutical And Biotechnology Companies
    Figure 15. Product Picture of Hospital
    Figure 16. Product Picture of Academic And Research Organizations
    Figure 17. Product Picture of Other
    Figure 18. Global Adenovirus Vector Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 19. Global Adenovirus Vector Vaccine Sales Value Market Share by Application, 2023 & 2030
    Figure 20. North America Adenovirus Vector Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 21. North America Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 22. Europe Adenovirus Vector Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 23. Europe Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 24. Asia Pacific Adenovirus Vector Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 25. Asia Pacific Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 26. South America Adenovirus Vector Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 27. South America Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 28. Middle East & Africa Adenovirus Vector Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 29. Middle East & Africa Adenovirus Vector Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 30. Key Countries/Regions Adenovirus Vector Vaccine Sales Value (%), (2019-2030)
    Figure 31. United States Adenovirus Vector Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 32. United States Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 33. United States Adenovirus Vector Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 34. Europe Adenovirus Vector Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 35. Europe Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 36. Europe Adenovirus Vector Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 37. China Adenovirus Vector Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 38. China Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 39. China Adenovirus Vector Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 40. Japan Adenovirus Vector Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 41. Japan Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 42. Japan Adenovirus Vector Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 43. South Korea Adenovirus Vector Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 44. South Korea Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 45. South Korea Adenovirus Vector Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 46. Southeast Asia Adenovirus Vector Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Southeast Asia Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 48. Southeast Asia Adenovirus Vector Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 49. India Adenovirus Vector Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 50. India Adenovirus Vector Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 51. India Adenovirus Vector Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 52. Adenovirus Vector Vaccine Industrial Chain
    Figure 53. Adenovirus Vector Vaccine Manufacturing Cost Structure
    Figure 54. Channels of Distribution (Direct Sales, and Distribution)
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation

Description

Adenovirus vector vaccine refers to the adenovirus as the carrier, the protective antigen gene is recombinant into the adenovirus genome, using the recombinant adenovirus can express the protective antigen gene made of vaccine.The characteristics of adenovirus vector vaccine showed that the adenovirus vector carrying various antigens can stimulate the body to produce strong humoral immunity or cellular immunity.In addition, since adenovirus vector can infect the respiratory tract and intestinal cells, it can facilitate immunity through the mucosa and induce the body to produce mucosal and systemic immune responses.

The global market for Adenovirus Vector Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

Market Segmentation